http://www.fpnotebook.com/
ChantixAka: Varenicline
- Indications
- Mechanism
- Nicotine binds nicotinic acetylcholine receptor a4b2
- Binding stimulates CNS mesolimbic Dopamine system
- Reinforces nicotine exposure
- Chantix activity
- Chantix Blocks nicotine at a4b2 receptors
- Chantix selectively binds a4b2 receptors
- Nicotine binds nicotinic acetylcholine receptor a4b2
- Dosing
- Start: 0.5 mg once daily on days 1 to 3
- Next: 0.5 mg twice daily on days 4 to 7
- Next: 1 mg twice daily
- Duration
- Continue for 12 weeks
- Additional 12 weeks may be used if successful
- Dosing adjustment: Renal Impairment
- Severe renal Impairment: Max dose 0.5 mg PO bid
- End-stage renal disease: Max dose 0.5 mg PO daily
- Adverse Effects
- Nausea (30%)
- Headache (10%)
- Sleep disturbance (Insomnia, or abnormal dreams): 10%
- Constipation
- Flatulence
- Suicidal Ideation
- Reported in 1 per 10,000 patients taking Chantix
- Kuehn (2008) JAMA 299(10):1121
- Cost
- Monthly: $120
- Efficacy
- Cessation for >1 year in 20% (10% with Placebo)
- Cessation rates are as good if not better than Zyban
- Number Needed to Treat (for longterm cessation): 9
- References
varenicline (C1569608) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C500838 |
| English | varenicline |
| Spanish | vareniclina |
| Parent Concepts | Benzazepines (C0005034), Drugs used to treat addiction (C1629845), A4beta2 acetylcholine receptor partial agonist (C1719875) |
| Sources | MSH, RXNORM, SCTSPA, SNOMEDCT, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Chantix (C1712042) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C500838 |
| English | Chantix |
| Sources | MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
